Lupus & antiphospholipid syndrome
Accrual of thromboembolic events and antiphospholipid syndrome in new-onset systemic lupus erythematosus: a population-based inception cohort study
Authors' conclusion
This population-level study reveals high risk of TE, particularly for aPL positive patients around the time of SLE diagnosis.
Study context
- Population
- All medical-record confirmed new-onset systemic lupus erythematosus (SLE) patients fulfilling 2019 EULAR/ACR classification criteria, Southeast Norway (population 2.9 million), 2000–2017mean follow-up 8 years (SD 5.0)
- Participants
- 700 participants
- Exposure
- aPL positive with antiphospholipid syndrome (APS) vs patients without APS; aPL-positive vs aPL-negative
- Outcome
- Key outcomes: APS, TE and death (incidence and timing of arterial and venous TE relative to SLE onset)
Methodological detailsKaplan-Meier methods
- Kaplan-Meier methods
Main finding
As reported in the abstract
New TE during follow-up · mean 8 years
Patients experiencing a new thromboembolic events (TE)
13%
89/700
Observational data: associations, not effects.
Further findings
TE incidence per 100 person-years, first year of SLE
TE incidence per 100 person-years, subsequent 4 years
| Outcome | APS | Without APS |
|---|---|---|
| Standardised mortality rate | 4.7 (95% CI 1.8–10.7) | 1.7 (95% CI 1.2–2.3) |
1-year TE-free survival in aPL-negative patients aged <50 years (lowest TE incidence)
- 1-year TE-free survival
- 0.99 (95% CI 0.97 to 1.0)
TE-free survival beyond the first year, aPL positive vs negative
- TE-free survival rates did not differ between SLE patients positive and negative for aPL
Original publication
Accrual of thromboembolic events and antiphospholipid syndrome in new-onset systemic lupus erythematosus: a population-based inception cohort study. RMD Open. Published 2 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →